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| INTRODUC TI ON AND CLINI C AL BACKG ROU N D
In 1976, Lyme disease was first described in the town of Old Lyme, Connecticut, USA. The disease was recognized as a tick-transmitted disease due to the geographical clustering of children with what was initially thought to be juvenile rheumatoid arthritis (RA). 1, 2 A couple of years later in 1981, the causal pathogen was identified as Borrelia burgdorferi. 3 The early localized form of the disease is diagnosed by identifying the pathognomonic erythema migrans (EM), often described as a bull's-eye rash around the tick bite. 3, 4 In a longitudinal observational study, about 60% of 55 untreated EM patients developed at least one attack of arthritis over the course of 4 years. 5 Since these cases, Lyme arthritis has been characterized as a mono-or oligoarthritis, typically presenting as a monoarthritis of the knee. Other signs of Lyme arthritis include joint swelling, synovial hypertrophy, vascular proliferation, and infiltration of immune cells. 6 The occurrence of Lyme arthritis differs between geographical regions due to the presence of various species of B. burgdorferi sensu lato, which are more likely to disseminate to a certain organ depending on their surface protein expression. 7 Since Borrelia garinii and Borrelia afzelii are more common in Europe, and B. burgdorferi sensu stricto, the strain more likely to disseminate to the joints, is predominantly observed in North America, Lyme arthritis is more common in this latter region. [8] [9] [10] [11] [12] [13] Lyme disease can be difficult to diagnose when clear pathognomonic signs, such as a typical EM, or the presence of a tick bite, have not been observed. Also, serological testing for Lyme disease has its limitations. Shortly after infection, antibodies can still be undetectable, and serological responses can be broken off due to antibiotic therapy. 14, 15 On the other hand, once formed, immunoglobulin G (IgG) antibodies can be detectable for years, even after the infection has passed. 16, 17 Incorrect diagnosis increases the risk of further advancement of Lyme disease in the patient while the infection could be effectively treated with antibiotics such as doxycycline. 18, 19 However, in a small percentage of patients, symptoms persist, even after antibiotic treatment, probably due to differences in disease development and recurrent inflammation ( Figure 1 ). 1 Lyme arthritis can manifest itself as early as 4 days or as late as 4 years after an EM. In untreated patients, it affects not only the knee joint but also other large or small joints. If left untreated, synovitis can continue for months up to years. 5 Usually, Lyme arthritis symptoms resolve after appropriate antibiotic therapy. In one study, resolution of arthritis has been observed in 80% of patients treated with doxycycline. 20 However, more recent studies describe residual synovitis after the first course of antibiotics in 34% and even up to 40% in patients treated with doxycycline. 21, 22 Even after repeated F I G U R E 1 Schematic representation of the possible course of (antibiotic-refractory) Lyme arthritis symptoms over time. In the majority of patients, arthritis symptoms resolve when antibiotic therapy is given. However, arthritis can persist in a subset of cases. Usually, these symptoms are present intermittently as is presented in this graph. A depiction of the (maladaptive) immune response is given below courses of antibiotic therapy, symptoms persist in some patients.
This condition is called antibiotic-refractory Lyme arthritis.
The most imperative question for both healthcare providers and patients remains if this is due to persistent infection and if additional courses of antibiotics should be prescribed. Persistence of B. burgdorferi infection as a cause for antibiotic-refractory Lyme arthritis seems unlikely based on several observations. 23 Firstly, polymerase chain reaction (PCR) for B. burgdorferi DNA in the synovial fluid is often negative in antibiotic-refractory Lyme arthritis patients, while it is positive at the onset of disease. [24] [25] [26] Likewise, a study on synovial samples collected by arthroscopic synovectomy in 26 antibiotic-refractory Lyme arthritis patients observed negative PCR results in all samples. 27 Secondly, in most cases cultivation of B. burgdorferi in synovial fluid cannot be performed or shows non-motile spirochetes. [28] [29] [30] Finally, recurrent or persistent Lyme arthritis often improves upon anti-inflammatory therapy. 31 In this review, we will discuss the role and interaction of B. burgdorferi with the innate and the adaptive immune response. We will describe this relationship during early infection, dissemination, and the development of persistent inflammatory reaction in some patients, resulting in antibiotic-refractory Lyme arthritis. This overview may generate directions for future research on the pathogenesis of Lyme arthritis.
| FROM S K IN INVA S I ON TO ARTI CUL AR JOINTS: INITIATI ON OF LYME ARTHRITIS
The dermis is the first tissue that the B. burgdorferi bacteria encounter once they enter the skin after tick inoculation. 32 It consists of a broad range of extracellular matrix (ECM) proteins and polysaccharide components and is particularly rich in collagen type I. 33 Tick saliva supports the spirochete to survive in the host tissues. Various tick salivary factors accommodate in the localized disruption of host tissues and immune responses. [34] [35] [36] [37] [38] Outer surface proteins (Osps) are widely expressed by the spirochete once established in the host and support the bacteria to evade the immune system through suppression of several immune recognition pathways. 39 Following skin inoculation, in some patients B. burgdorferi may spread throughout the human body, targeting specific tissue sites. This can cause a diverse range of symptoms, from chronic neurological complications to carditis, skin abnormalities and damage to the host's joints. 5, [7] [8] [9] [10] [11] [12] [13] Borrelia species dissemination may occur through two routes: hematogenous and non-hematogenous. [40] [41] [42] [43] Non-hematogenous spread transpires via the lymphatic system. Upon hematogenous dissemination, Borrelia species translocate through the endothelium and ECM of the vasculature, crossing the last remaining tissue barriers to arrive at the target site. [44] [45] [46] [47] Borrelia species preferentially target the heart or articular joints or cross the blood-brain barrier. 1, 7 Microvascular interactions of Borrelia spirochetes in murine skin were visualized using epifluorescence and spinning disk confocal intravital microscopy. These images showed that following inoculation the bacterium was localized in the capillaries, postcapillary venules, and large veins. After encountering the vascular endothelium, Borrelia bacteria tethered to the endothelial cells and underwent dragging interactions in the direction with the blood flow, followed by stationary adhesion. 45 Plentiful Borrelia lipoproteins bind to ECM components and may be involved in the tethering of Borrelia bacteria to the vascular endothelium. [46] [47] [48] Fibronectin and glycosaminoglycans (GAGs) potentially mediate these interactions. 49 Spirochaetal lipoproteins have also been observed to interact with integrins of primary human chondrocytes, triggering myeloid differentiation primary response 88 (MyD88)-independent inflammatory pathways and eventually leading to the development of Lyme arthritis. 50, 51 Fibronectin binding may generate enough time for integrins to bind to the vascular wall, thereby supporting the contact of pathogen and host. 52 BBK32 is a B. burgdorferi surface protein that binds to fibronectin, 44, 49, 53, 54 possibly through the utilization of lectin binding sites or other molecules. Several other B. burgdorferi proteins have also been identified as fibronectin-binding proteins, including RevA, RevB, and BB0347. 55, 56 Borrelial lipoprotein decorin-binding protein A (DbpA) can bind decorin, heparin, and dermatan sulfate GAGs 48, 57, 58 and is widely expressed in skin and cartilage tissue. 59, 60 B. burgdorferi dissemination to the joints has been correlated with the expression of this DbpA gene, and the presence of spirochetes has been associated with the amount of decorin found in host tissues. 61 Moreover, decorin in the host was observed to be required for the development of Lyme arthritis in mice. 62 While decorin is important in B. burgdorferi adhesion and invasion, it has also been suggested that the spirochete is able to directly bind to intact collagen. A study using hydrated collagen type I lattices of B. burgdorferi adhesion without decorin showed that the bacteria were still able to bind to the collagen matrix, even if glycosaminoglycan chain degrading enzymes were added to the matrix or if an agar matrix, bovine serum albumin, gelatin, or pepsinized type I collagen was utilized. In contrast, B. burgdorferi adhesion to collagen was shown to diminish in the absence of flagella and by proteinase K treatment, demonstrating that B. burgdorferi surface proteins play an important role in collagen binding. 63 GAGs seem to further promote Borrelia spirochete adhesion to the collagen. 63 Therefore, these above-mentioned molecules and structures may be important in B. burgdorferi association with intact type I collagen matrices.
B. burgdorferi also expresses peptidoglycans, which may be recognized by the human immune system. Recently, human IgG responses against B. burgdorferi peptidoglycan have been related to worsening of Lyme arthritis in the long term. 64 After adhering to the endothelium, B. burgdorferi traverses the endothelial cell monolayers through tight junctions. 65, 66 Borrelia P66 protein can form an OM β-barrel porin that adheres to host β1 and β3 chain integrins. The β1 chain is crucial in Borrelial internalization and transmigration across cellular junctions. P66 may assist in the intracellular invasion of B. burgdorferi as well. [67] [68] [69] Furthermore, P66 is known to associate with OspA and OspB. 70 High-temperature requirement protease A is a well-known family of adenosine triphosphate-independent serine proteases that can break down ECM components. B. burgdorferi encodes such a protease, supporting Borrelial tissue invasion through ECM degradation. 71 Another Borrelia host target is aggrecan, a proteoglycan commonly found in cartilage ECM. 62, 72 The enzymes responsible for the degradation of aggrecan, called aggrecanases, have been shown to be induced in human chondrocytes infected with B. burgdorferi. 72, 73 One of these aggrecanases is ADAMTS-4. Active forms of ADAMTS-4 were significantly increased in the synovial fluid samples of patients with active Lyme arthritis and Borrelia-infected mice. 72 ADAMTS-5 was not elevated in Lyme arthritis, but is prominent in osteoarthritis. 72, 74 ADAMTS-4 may therefore be an aggrecanase induced differentially from ADAMTS-5. This differential expression may be specifically associated with cartilage damage in Lyme arthritis.
B. burgdorferi also activates the host enzyme plasmin via Osp binding. 55, [75] [76] [77] By binding plasminogen, B. burgdorferi promotes its conversion to plasmin by a host-derived activator, thereby further promoting the degradation of ECM components, through the activation of matrix metalloproteinases (MMPs). 55, [75] [76] [77] [78] [79] [80] Plasmin activates pro-MMP forms of MMP-1, MMP-3, MMP-10, and MMP-13, enzymes involved in degrading the ECM. [81] [82] [83] [84] [85] [86] This degradation may support the host to clear the infection, but conversely, it may also promote spirochete dissemination or the development of Lyme arthritis. 78, [87] [88] [89] The intricate balance in the immune and tissue repair responses seems to play an important role in whether the infection may develop into a hyperinflammatory response that damages the joints or helps the host in tackling the infection.
B. burgdorferi can directly induce the production of several MMPs by host cells as well. In human chondrocyte cultures with the bacterium, an increased production of MMP-1, MMP-3, MMP-13, and MMP-19 was demonstrated, 87, [90] [91] [92] whereas Borrelia-stimulated monocytes produced MMP-9 and MMP-10. 78, 93, 94 In blister fluid from human EM lesions, MMP-9 expression was selectively increased compared with blister fluid from normal-appearing skin. 95 Moreover, antibiotic-refractory Lyme arthritis patients have higher levels of MMP-3 in their serum and synovial fluid, though antibodies against these enzymes were less common.
Furthermore, synovial fluid concentrations of interferon-gamma (IFN-γ)
and tumor necrosis factor-alpha (TNF-α), as well as T-cell chemoattractants CXCL9 and CXCL10, were significantly higher. [96] [97] [98] The expression of these cytokines and chemokines may stimulate tissue-resident cells to express degrading enzymes such as MMP-10.
These studies give an overview of the broad range of host and B. burgdorferi molecules, proteins, and tissues involved early in infection, further complicating Borrelia infection and the immune responses against this invading pathogen. Some of these host and bacterial factors have been shown to be involved in the initiation of Lyme arthritis or even lead to such a hyperinflammatory reaction that antibiotic therapy is no longer an effective treatment strategy ( Figure 2 ).
| INITIATI ON AND DE VELOPMENT OF ANTIB I OTI C-REFR AC TORY LYME ARTHRITIS
Over the last years, several hypotheses on the precise mechanism behind the development of antibiotic-refractory Lyme arthritis have been introduced. Both autoimmune responses and remaining bacteria or bacterial antigens have been suggested to contribute to this process. 25, 99 Borrelia DNA has been shown to be present in the synovial tissue of Lyme arthritis patients. 25 A recent study described persistence of flagellin B DNA and uncultivable B. burgdorferi in a range of murine heart muscle, joint, and muscle tissues and at the inoculation site up to 12 months after antibiotic treatment. 100 Also, spirochete remnants were found within joint entheses and adjacent to cartilage after ceftriaxone and doxycycline treatment. This was studied in MyD88 knockout mice that lack the crucial adapter protein for several innate recognition receptors called Toll-like receptors (TLRs), thereby allowing Borrelia spirochetes to survive. Interestingly, these spirochete remnants induced IgG antibodies to B. burgdorferi in naive mice and triggered macrophages to produce TNF-α in vitro. 101 In contrast to mice, pathogen loads in human Lyme arthritis are low. 24 However, these studies suggest that the persistence of dead spirochetes in the joint may cause an immunogenic response, resulting in prolonged inflammation in these tissues.
Autoimmune responses have been suggested to contribute to the pathogenesis of Lyme arthritis. The observation that specific human leukocyte antigen-DR isotype (HLA-DR) alleles such as DRB1*0401, crucial in binding of B. burgdorferi OspA, are more frequent in patients with antibiotic-refractory Lyme arthritis than in those responding to treatment. 102 Molecular mimicry is another autoimmune mechanism that is potentially involved in the development of antibiotic-refractory Lyme arthritis. Partial sequence homology has been observed between OspA and human lymphocyte function-associated antigen 1 (LFA-1), MAWD-BP, and human cytokeratin-10. 103, 104 Other possible targets for molecular mimicry with Borrelia bacteria are MMPs as well as several non-protein antigens and neural proteins. [105] [106] [107] [108] [109] [110] Endothelial cell growth factor (ECGF) is an autoantigen, targeted by T-and B-cell responses in around 20% of the antibiotic-refractory Lyme arthritis patients and in 15% of EM patients. 111, 112 These ECGF antibody responses correlated directly with the extent of obliterative lesions and the amount of vascularity in the tissue. ECGF is an IFN-inducible protein and is highly expressed in the synovial fluid of patients suffering from antibiotic-refractory Lyme arthritis compared to antibiotic-responsive Lyme arthritis. 112, 113 In archival serum samples from 27 untreated patients with Lyme arthritis, 26% of the samples showed ECGF antibody responses. The total duration of active arthritis attacks in these patients was significantly longer than in those who lacked ECGF reactivity. Compared to other rheumatological chronic inflammatory diseases, synovial tissue from Lyme arthritis patients consisted of significantly greater layer thickness and cellular infiltration. Obliterative microvascular lesions were observed in patients with Lyme arthritis only, whereas these lesions were not reported in RA. 112 The presence of these lesions was correlated with autoantibody responses to ECGF. ECGF autoantibodies are produced early in Lyme infection, months before the onset of arthritis and obliterative microvascular lesions. 111, 112 This implies that autoantibodies play a role in the development of these microvascular lesions and thereby in antibiotic-refractory Lyme arthritis. Non-human primate studies have shown that obliterative microvascular lesions may not just be specific for Lyme arthritis, but may be a more general consequence of spirochaetal infections. [114] [115] [116] [117] Lyme arthritis patients are prone to enhanced inflammatory responses. Patients carrying a particular TLR1 polymorphism develop a strong innate and adaptive immune reaction, resulting in high TNF-α, interleukin (IL)-1β, and IFN-γ concentrations in the joints. 97, 98 IFN-γ stimulates ECGF production by macrophages and other cells, leading to vascular proliferation and fibroblast activation. As mentioned above, T-and B-cell responses to ECGF were found in only a small number of EM patients. 111, 112 However, if these ECGF responders were more prone to develop Lyme arthritis was not further investigated. 112 Not only ECGF, but also apolipoprotein B-100, annexin A2, N-acetylglucosamine-6-sulfatase, and filamin A-derived peptides may induce T-cell responses in Lyme arthritis patients, usually already early in the infection, when EM is apparent. 99, 111, 118, 119 Antibiotic-refractory Lyme arthritis patients have higher levels of MMP-3 in their serum and synovial fluid, though antibodies against these enzymes were less common. Furthermore, synovial fluid concentrations of IFN-γ and TNF-α, as well as T-cell chemoattractants CXCL9 and CXCL10, were significantly higher. [96] [97] [98] The expression of these cytokines and chemokines may stimulate tissue-resident cells to express degrading enzymes such as MMP-10.
Furthermore, a MMP-10-derived peptide was isolated from an antibiotic-refractory Lyme arthritis patient's synovial tissue. This peptide could also be bound by HLA-DR sequences. Subsequently, the role of MMP-10 was studied in various Lyme patient groups.
A marked T-cell response was observed in 25% of the antibiotic-refractory patients and MMP-10 autoantibody levels were correlated with a worse phenotype of Lyme arthritis. However, as the authors suggest, this single autoantibody response is likely not solely responsible for the development of (antibiotic-refractory) Lyme arthritis. 99 F I G U R E 2 Lyme arthritis: a joint effort. A, The initiation of Lyme arthritis through enhanced cytokine and chemokine production by both macrophages and dendritic cells, as well as neutrophil formation of extracellular traps (NETs) and tissue-resident cells such as chondrocytes producing matrix metalloproteinases (MMPs). Of these factors IL-1β, IFN-γ, IL-17, CXCL9, CXCL10, and MMPs are shown in red because they play a major role in worsening the disease development and whose levels are often enhanced in patients with antibiotic-refractory Lyme arthritis. B, The progression of Lyme arthritis, causing a more chronic phenotype with high numbers of (effector) T cells, initiated via dendritic cell stimulation of T-cell receptors using either Borrelia or self-antigens, without the necessary presence of live Borrelia spirochetes, and antibody production from activated B cells. The continued presence of activated innate immune cells further heightens the number of activated adaptive immune cells and cytokines and chemokine levels
| THE ROLE OF THE INNATE IMMUNE SYS TEM DURING THE E ARLY S TAG E S OF BORRELIA INFEC TI ON
After initial Borrelia infection of the skin, an influx of immune cells from the peripheral blood occurs. Polymorphonuclear leukocytes (PMNs) play an important role in infections. Freshly isolated human PMNs are shown to eradicate spirochetes mostly through antibodyindependent extracellular killing processes such as reactive oxygen species (ROS) production, whereas differentiated monocyte-derived macrophages ingest the bacteria and kill the spirochetes without the necessity of opsonization. 120, 121 When the tick feeds on a human host, both the bacteria and the tick saliva are released and encounter the accumulating immune cells, influencing the host defense responses. 34, 35, 122 Neutrophils are recruited very early at the site of infection. They are able to kill pathogens by a range of defense mechanisms such as phagocytosis, ROS production, and extrusion of their nuclear DNA with elastase and myeloperoxidase, leading to formation of neutrophil extracellular traps (NETs), to capture invading pathogens. [123] [124] [125] In vitro incubation of human neutrophils and in vivo infection of mice with B. burgdorferi combined with saliva or salivary gland extracts induced NET formation. NETs can trap and kill Borrelia spirochetes. 126 Human neutrophils are directly activated by B. burgdorferi through interaction with OspA. 127 B. burgdorferi is sensitive to ROS and granule enzymes in an in vitro setting, in the absence of tick saliva. 128 However, tick salivary factors impair neutrophil actions at the site of infection 34, 129 and there is a lack of neutrophils in EM lesions. 130 Moreover, Borrelia spirochetes have developed a range of neutrophil evasion mechanisms, including the inhibition of IL-8 secretion, a cytokine involved in neutrophil recruitment, by Evasin-E3, 131 inhibition of neutrophil chemotaxis through N-formylmethionyl-leucyl-phenylalanine activation, and interference of OspB with neutrophil phagocytosis, possibly through direct interaction with the complement receptor 3 (CR3) and oxidative bursts via unknown mechanisms. 132, 133 Using rapid movements, the spirochetes can also escape neutrophil interaction. Neutrophil migration is inhibited by binding of the tick saliva leukotriene B4, enhancing bacterial propagation and formation of EM. 134 Tick saliva further interferes with neutrophil function through downregulation of neutrophil integrin expression, inhibition of superoxide anions production and elastase inhibition. 135, 136 Previous studies have shown that a diminished neutrophil response may increase the hosts' susceptibility to Borrelia infection, whereas increased recruitment of neutrophils early in infection may reduce dissemination of Borrelia to the joint. 130 During infections, neutrophils produce IL-1β, TNF-α, IL-8, and IL- A role for NK cells in the initiation of Lyme arthritis is postulated by several studies. C57BL/6 mice genetically deficient in granulocytes and NK cells developed less severe arthritis than their wildtype counterparts. 143 However, depletion of NK cells did not influence the course of arthritis, 144 suggesting NK cells augment the development of Lyme arthritis. OspA augments the activation of NK cells, 145 which can drive the induction of various inflammatory mediators, including TNF-α. 146 Anti-TNF-α therapy has been described to be effective in antibiotic-refractory Lyme arthritis. 147 Spread of B. burgdorferi is hampered by the ability of macrophages and dendritic cells to bind and phagocytize B. burgdorferi. [150] [151] [152] Spirochetes ingested by macrophages are quickly localized in endosomes and lysosomes. 153 However, in severe combined immunodeficiency (SCID) and C3H/HeN murine studies with peritoneal macrophages, OspC was shown to protect the spirochete against phagocytosis. 154 Depletion of mononuclear phagocytes in these mice permitted non-functional OspC Borrelia mutants to initiate infection in vivo. Increased OspC expression also reduced spirochete uptake by murine peritoneal macrophages, suggesting a role for OspC in anti-phagocytic function. 154 Furthermore, OspC was shown to interfere in plasminogen function and promote spirochete invasiveness. 75, 155, 156 Thus, B. burgdorferi effectively uses its Osps to avoid phagocytosis.
In EM lesions, large populations of monocytes, macrophages, and dendritic cells are observed. 157 Interaction of murine macrophages with Borrelia antigens induces production of nitric oxide, IL-1, TNF-α, IL-6, and IL-12, 145 and MMP-9. 95 Intriguingly, LSH hamsters injected with macrophages that were previously exposed to B. burgdorferi developed severe, destructive arthritis. In contrast, animals that received unprimed macrophages did not develop arthritis. 158 Furthermore, the combination of primed macrophages and T cells accelerated the development of arthritis in Borrelia-infected ICR mice compared to either one alone. 159, 160 This highlights the impor- 
Inhibition of myostatin in vivo suppressed Lyme arthritis in reduced
interval congenic Bbaa1 mice, implicating that myostatin is a downstream mediator in Lyme arthritis. 161 Receptor-blocking antibodies and receptor ablation showed the crucial role of type I IFN production by macrophages in Lyme arthritis severity. 162, 163 Increased IFN-γ signaling in macrophages also enhances indoleamine-pyrrole 2,3-dioxygenase levels. 164 This is a molecule regulating ROS, collagenase, elastase, and stromelysin activity, 165 thereby increasing ECM degradation. Destabilization in the membrane structure of murine cells results in adherence of spirochetes remnants to the cartilage. 101 These Borrelia remnants may, in turn, initiate an inflammatory reaction and stimulate TNF-α production by macrophages. 164 Many studies of Lyme arthritis are performed in mice, due to the limited number of Lyme arthritis patients and available tissue specimens. Murine models are not completely comparable to human Lyme arthritis, and large differences in disease expression are observed between different mouse strains. C3H/HeN mice, for example, are highly susceptible to Borrelia-induced arthritis once the bacteria are injected into the joint. These mice have a defect in IL-12 production, which hampers the induction of IFN-γ through IL-12/IL-18 signaling.
This possibly explains why these mice are more susceptible to invading bacteria. 166 In contrast, C57BL/6 mice do produce IFN-γ upon Borrelia exposure. 167 TLRs are cell receptors that recognize conserved molecular patterns on microbial components, such as lipoproteins, lipopolysaccharide, proteoglycans, flagellin, and nucleic acids. Binding of TLRs with these components results in NF-κB-mediated expression of pro-inflammatory cytokines. TLR2-deficient mice were shown to have a significant increase in the number of spirochetes in their joints after infection compared to WT mice. 157 170, 171 A recent study in C3H/HeN mice showed that this increase may be attributed to CD8 T-cell activation of synoviocytes. 171 Moreover, transcripts for the IFN-inducible gene IFN-γ-induced GTPase were elevated. 170 Intriguingly, recent studies have shown that TLR2 can function as a co-receptor on activated T cells, influencing their responses and function. 172 However, when compared to wildtype control mice, TLR2-deficient mice had higher Borrelial load but no significant difference in joint swelling, 169 while increases in swelling and arthritis have been reported in Borrelia-infected TLR2-deficient C57BL/6 mice in another study. 168 The co-receptor CD14 is crucial in Borrelia recognition in collaboration with TLR2. [173] [174] [175] [176] Interestingly, a study by Sahay et al 177 suggests that CD14 may be important in Borrelia clearance and tolerization of macrophages, through SOCS1 and SOCS3 signaling, whose pathways have also been linked to MMP production and degradation of collagen. 178, 179 CD14 deficiency in mice reduced these effects significantly and led to higher bacterial burdens and more severe and persistent inflammation. 177, 180 However, the murine studies demonstrated a possible link between CD14 signaling and persistent inflammation in Lyme arthritis. Yet, it is still unclear whether this is caused by inhibition of TLR2 signaling or by the direct function of CD14 itself.
The intracellular NOD2 receptor has also been shown to be involved in Borrelia recognition. 181 Remarkably, B. burgdorferi infection of NOD2 deficiency C57BL/6 mice led to increased inflammation in joints and cardiac tissue when compared to wildtype mice, suggesting that NOD2 tolerization normally protects these mice against dissemination, possibly through the induction of multiple cytokines and interferons. 182 pathway was crucial for IL-1β production. Borrelia-exposed NOD1-, NOD2-, and RICK-deficient murine cells still produced IL-6 and TNFα. In contrast to previous in vitro data, NLRP3 did not seem to be involved in Lyme arthritis development in a murine model. [183] [184] [185] [186] ASC was pivotal in Lyme arthritis initiation as an important adapter protein in the inflammasome, involved in antigen presentation, lymphocyte migration, NF-κB activation, and messenger RNA (mRNA) stability and via dedicator of cytokinesis 2 (Dock2) expression and Rac activation. 187 183 It would be interesting to study whether NOD signaling is involved in IL-1Ra production and thereby in the attenuation of Lyme arthritis.
Another innate regulatory mechanism in Lyme arthritis is the expression of microRNAs (miRNAs). miRNAs are small, non-coding RNA molecules that can bind mRNA and inhibit its translation. They are expressed by various innate immune cells, such as monocytes, macrophages, DCs, granulocytes, and NK cells. miRNAs are crucial in the development and function of innate immune cells and play a role in adaptive immune cell regulation. 188, 189 Dysfunction of miRNAs can induce inflammatory diseases and autoimmunity. 190 In mouse studies, several miRNAs are reported to modulate experimental models of arthritis, including miR- 155, 191 miR-223, 192 and miR-146a. 193 This is consistent with the role of miRNAs in RA. 194 Intriguingly, mice lacking either miR-146a or miR-155 were shown to develop more severe Lyme arthritis or carditis. 195, 196 Recently, in groups of patients with different stages of Lyme arthritis, alternate miRNA profiles were observed. Elevated levels of miR-223 and low levels of miRNAs such as miR-146a, miR-155, and miR-142 were found in synovial fluid of Lyme arthritis patients prior to antibiotic therapy (n = 5). Also, elevated levels of white blood cells, specifically PMNs, were found in SF of these patients. 197 In contrast to postantibiotic persistent Lyme arthritis patients (n = 13), who had higher percentages of lymphocytes and mononuclear cells, and a high expression of miR-146a, miR-155, miR-142, miR-233, and miR-17-92. Let-7a family levels were reduced. 197 Of note, arthritis in two of these 13 patients resolved after intravenous administration of antibiotics. miRNA expression in patients with postinfectious Lyme arthritis was most similar to the expression in RA patients, where miR-155, miR-146a, and miR-223 were prominent in the synovial fluid, synovial tissue, and synovial fibroblasts. 198 Higher levels of miR-146a, miR-17, and miR-233 are also correlated with increased duration of Lyme arthritis. 197 function of TLR2 and TLR5 polymorphisms did not vary between the patient groups. However, previous murine studies have suggested that TLR2 may play a role in the severity of Lyme arthritis. 170, 199 This may be partially explained by the fact that this TLR2 polymorphism does not abolish TLR2 function, as only one allele is affected.
Moreover, this allele is present in only a low proportion of patients with a wide range of manifestations of Lyme disease, including EM, ACA, and Lyme arthritis. 200 Nevertheless, this is of interest, since the TLR1/TLR2 heterodimer recognizes Borrelia lipopeptides as a complex. 201, 202 It is unclear how Borrelia infection in humans with the 1805GG polymorphism or in mice with TLR2 deficiency results in a heightened Th1 response. 98 The cells with the SNP might recognize different peptides, activate the adaptive immune cells using a different mechanism, or affect a whole recognition pathway. In murine macrophages stimulated with B. burgdorferi, TLR1/2 complex deficiency resulted in persistent augmented levels of inflammatory cytokines and chemokines due to a significant reduction in p38 activation and SOCS expression. 177 Interestingly, IFN-responsive gene induction was shown to occur independently of TLR2, TLR4, TLR9, and MyD88, suggesting that B. burgdorferi activates another type I IFN transcription pathway through a different receptor or sensing molecule. 162 
| FROM INNATE INITIATI ON TO ADAP TIVE DYS REG UL ATION
The innate immune system is the key initiator of Lyme arthritis drivers for B. burgdorferi tissue damage and Lyme arthritis. In contrast, the adaptive responses control the pathogen, primarily using antibody production, and may in a later stage contribute to immune dysregulation in the joints. 162, 203 The predominant innate immune cells seem to differ in several manifestations of Lyme disease, and so the innate pathways may differ. 204 The importance of innate immune cells was studied in mice without both B and T cells. The authors observed that innate immune cells are crucial in Lyme arthritis commencement and adaptive immune cells are not the direct cause of Lyme arthritis initiation and probably only worsen the disease symptoms. 99, 162 Moreover, innate immune cells are responsible for the production of MMPs, HLA-DR subsets, and signaling involved in the disease, as well as for induction of IFN production, through other IFNs, IL-12, and IL-18. 81, 102, 162, 183 In in Lyme arthritis. The role of IL-17 has been elaborated in several studies. In an experimental mouse study, IL-17 inhibition prevented the development of Lyme arthritis. 211 In patients with Lyme arthritis, Th17 cells were observed in the synovial fluid. 212 Moreover, B. burgdorferi or its lipoproteins were shown to be able to induce the production of IL-17 in vitro. 213, 214 In addition, synovial T cells, extracted from patients with Lyme arthritis, produced IL-17 in response to
Borrelial antigen neutrophil-activating protein A. 215 IL-17 production was shown to be caspase-1-and IL-1β-dependent, through the activation of IL-17-producing T cells. In the absence of IL-1β, a defective IL-17 production was observed, while IL-18, a cytokine which is also caspase-1-dependent, was vital for IFN-γ production in Lyme arthritis. Caspase-1-dependent IL-33 did not play a role in Borrelia-induced IL-1β, IFN-γ, or IL-17 secretion. 167 Patients with antibiotic-refractory Lyme arthritis have remarkably high levels of the innate mediator IL-6 in their synovial fluid, which is vital for Th17 lineage specification. 216 IL-23 levels are also enhanced, which may polarize Th17 cells toward a more pathogenic phenotype throughout the course of the disease, due to enhanced infiltration of inflammatory myeloid cells into the tissue. 217, 218 In of active caspases in human T cells showed that caspase-3, but not its upstream initiator caspase-8 or caspase-9, is elevated in Lyme arthritis. 223 These active caspases seem to appear in lipid rafts at the cell membrane during T-cell cycling 224, 225 ; thereby, their access to cytoplasmic substrates involved in cell death is denied. The prominent caspase-3 activity may be caused by more intense TCR signaling in T cells, resulting in a rapid effector T-cell response. Moreover, this activation may be related to the Fas-associated death domain-like IL-1 expression. 223 Of high interest, recent research proposes that Fas:FasL signaling between CD4 T cells, DCs, and γδ T cells may be part of the inflammatory reaction in (antibiotic-refractory) Lyme arthritis. 226 The synovium from Lyme arthritis patients contains high levels of CXCL10, a chemokine specific for Th1 cells, and CCL2, important for both Th1 and Th17 recruitment via CXCR3 expression. 97 PMNs are well known for producing these chemokines in response to LPS or IFN-γ [227] [228] [229] 
| THER APY OF LYME ARTHRITIS
As is the case in localized early Lyme disease, timely antibiotic treatment is recommended for Lyme arthritis. [230] [231] [232] This is based on several double-blinded randomized trials. Efficacy was first investigated in a parental penicillin trial. 233 In this study, 35% of patients had complete resolution compared to none of the placebo-treated patients. The percentage of patients with resolution of Lyme arthritis was higher in trials on doxycycline therapy. 20, 23 Oral therapy was shown to be as effective as IV therapy, but safer and less expensive. 234 Furthermore, antibiotic treatment shortens the duration of Lyme arthritis considerably. The clinical course of 21 patients with EM and Lyme arthritis treated with non-steroidal anti-inflammatory drugs and intra-articular steroids without antibiotic treatment was described in the 1980s. 5 These individuals had attacks of arthritis, ranging from short attacks of arthritis to continuous synovitis, for a median total time of 43 months, 5 whereas the duration of arthritis in antibiotic-treated patients ranged from a median of 4 months in an antibiotic-responsive group (n = 50) to 16 months in an antibioticrefractory disease group (n = 62). 23 In most patients with Lyme arthritis, symptoms resolved after a single course of antibiotic therapy, but this proportion varies from 48% to 90% in both Europe 22, 235, 236 and North America. 20, 23, 237 In the case of persistent arthritis, a second course of antibiotics could be given. Often, in persistent severe or worsening cases IV therapy with ceftriaxone is chosen because of its reported effectiveness. 238 Another option is to wait for 3 months before retreatment is commenced, 230 because resolution of Lyme arthritis might occur months after a first course of antibiotic therapy. 20, 23 Other therapeutic approaches for antibiotic-refractory Lyme arthritis may be considered, for example treatment strategies employed against other forms of inflammatory arthritis (ie, RA).
Unfortunately, randomized trials with DMARDs are lacking. In vitro studies suggest an effect of hydroxychloroquine against B. burgdorferi, 239, 240 and there are studies reporting the potential benefits of this drug as an antirheumatic drug 241, 242 ; however, no data are available in patients with Lyme arthritis. While randomized controlled clinical trials are lacking for systemic anti-inflammatory regimens, DMARDs have been shown to reduce symptoms of inflammation and patients benefit from this therapy in clinical practice. TNF inhibitors (ie, tocilizumab) are suggested to have a clinical beneficial effect as well, although there have been concerns about the risk of infection with such immune suppressive therapy. [243] [244] [245] Arthroscopic synovectomy is another therapeutic option, when the response to a DMARD is incomplete and the arthritis is limited to one joint. 246 Intra-articular corticosteroids are not recommended during the second period of antibiotic therapy, 230 
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